BRD9 and acute myeloid leukemia: Given the extensive overlap between BRD9 inhibition and FDA-approved AML chemotherapy targets, the ability of I-BRD9 to specifically inhibit AML cell growth, and the release from impaired differentiation prompted by I-BRD9 treatment, BRD9 bromodomain inhibition may provide a tractable chemotherapeutic opportunity for AML treatment.